Acinetobacter baumannii (A. baumannii) infections are a clinical challenge; it is hard to treat due to elevated antibiotic resistance (multi-drug resistance) and elevated risk of resistance during treatment. Carbapenems and fluoroquinolones are therapeutic options for Gram-negative bacilli diseases including strains (A baumannii). New Delhi Metallo-β-lactamase-1 (blaNDM-1) gene, an acquired class B carbapenemase. The distribution includes mainly bland-1 gene transfer among promiscuous plasmids and clonal infections. The genes of quinolone resistance, such as the one family, can be transmitted horizontally and lead to decreased fluoroquinolone susceptibility. To investigate the prevalence of bland-1 and qnrA resistance genes in Acinetobacter baumannii isolated from patients with different infections in Al-Hillah hospitals. This cross-sectional study involved collecting 200 clinical samples from three main hospitals in the province of Babylon. Samples were inoculated for the biggest isolation in MacConkey and blood agar, followed by biochemical exams to confirm Acinetobacter.baumannii diagnosis. Using the disk diffusion technique, the susceptibility test for 14 kinds of antibacterial drugs was evaluated. Special techniques were used to extract chromosomal and plasmid DNA. Out of 40 Acinetobacter baumannii isolates, there were 16 isolates (40%) positive for the bland-1 gene and 20 isolates (50%) positive for the NRA gene. In Conclusion, Multidrug resistance Acinetobacter baumannii to carbapenems (Imipenem and Meropenem) and quinolones (Ciprofloxacin and Levofloxacin) was carried two genes have a role in the resistance. The bla NDM-1gene is associated with the resistance to carbapenems specially IMP and MEM. The NRA-gene is associated with the resistance to quinolones especially (Ciprofloxacin and Levofloxacin).